Efficacy of tiotropium in the prevention of exacerbations of COPD

Therapeutic Advances in Respiratory Disease

Volumn 3, Issue 3, 2009, Pages 103-111

  Anzueto, Antonio ^a   Miravitlles, Marc ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

clinical trials; COPD; exacerbations; tiotropium

Indexed keywords

BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST OF ILLNESS; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 68549118998     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465809338854     Document Type: Review

References (49)

1. Aaron, S.D., Vandemheen, K.L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R. et al. (2007) Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 146: 545-555.
2. Almagro, P., Calbo, E., Ochoa de Echaguen, A., Barreiro, B., Quintana, S., Heredia, J.L. et al. (2002) Mortality after hospitalization for COPD. Chest 121: 1441-1448.
3. Anzueto, A. and Miravitlles, M. (2008) Modifying the clinical course of COPD. Hot Topics Resp Med 7: 7-19.
4. Barr, R.G., Bourbeau, J., Camargo, C.A. and Ram, F.S.F. (2006) Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61: 854-862.
5. Brusasco, V., Hodder, R., Miravitlles, M., Korducki, L., Towse, L. and Kesten, S. (2003) Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58: 399-404.
6. Burrows, B., Bloom, J.W., Traver, G.A. and Cline, M.G. (1987) The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 317: 1309-1314.
7. Casaburi, R., Mahler, D.A., Jones, P.W., Wanner, A., San Pedro, G., ZuWallack, R.L. et al. (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19: 217-224.
8. Casaburi, R., Kukafka, D., Cooper, C.B., Witek Jr, T.J. and Kesten, S. (2005) Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127: 809-817.
9. Casanova, C., Cote, C., de Torres, J.P., Aguirre-Jaime, A., Marin, J.M., Pinto-Plata, V. et al. (2005) Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 591-597.
10. Cazzola, M., MacNee, W., Martinez, F.J., Rabe, K.F., Franciosi, L.G., Barnes, P.J. et al. (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31: 416-468, on behalf of the American Thoracic Society/European Respiratory Society task force on outcomes of COPD.
11. Celli, B., ZuWallack, R., Wang, S. and Kesten, S. (2003) Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124: 1743-1748.
12. Connors Jr, A.F., Dawson, N.V., Thomas, C., Harrell Jr, F.E., Desbiens, M., Fulkerson, W.J. et al. (1996) Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154: 959-967.
13. Donaldson, G.C., Seemungal, T.A.R., Bhomik, A. and Wedzicha, J.A. (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847-852.
14. Donaldson, G.C., Wilkinson, T.M., Hurst, J.R., Perera, W.R. and Wedzicha, J.A. (2005) Exacerbations and time spend outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 446-452.
15. Doll, H. and Miravitlles, M. (2005) Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature. Pharmacoeconomics 23: 345-363.
16. Dusser, D., Bravo, M.L. and Iacono, P. (2006) The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27: 547-555.
17. Freeman, D., Lee, A. and Price, D. (2007) Efficacy and safety of tiotropium in COPD patients in primary care - the Spiriva Usual Care (SPRUCE) study. Respir Res 8: 45.
18. Fuso, L., Incalzi, R.A., Pistelli, R., Muzzolon, R., Valente, S., Pagliari, G. et al. (1995) Predicting mortality of patients hospitalized for acute exacerbated chronic obstructive pulmonary disease. Am J Med 98: 272-277.
19. Gompertz, S., Bayley, D.L., Hill, S.L. and Stockley, R.A. (2001a) Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 56: 36-41.
20. Gompertz, S., O–Brien, C., Bayley, D.L., Hill, S.L. and Stockley, R.A. (2001b) Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 17: 1112-1119.
21. Groenewegen, K.H., Schols, A.M. and Wouters, E.F. (2003) Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124: 459-467.
22. Gross, N.J. (2007) Tiotropium bromide. Hot Topics Resp Med 5: 15-19.
23. Hodgev, V.A., Kostianev, S.S., Torosian, A.A., Yanev, I.B. and Mandoulova, P.B. (2004) Long-term changes dyspnea, lung function, and exercise capacity in COPD patients. Folia Med 46: 12-17.
24. Johansson, G., Lindberg, A., Romberg, K., Nordström, L., Gerken, F. and Roquet, A. (2008) Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 17: 169-175.
25. Mannino, D.M., Homa, D.M., Akinbami, L.J., Ford, E.S. and Redd, S.C. (2002) Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ 51: 1-16.
26. Martinez, F.J. (2006) Acute exacerbations of chronic bronchitis and COPD: definition and impact. Hot Topics in Resp Med 1: 7-12.
27. Miravitlles, M., Mayordomo, C., Artés, M., SánchezAgudo, L., Nicolau, F. and Segú, J.L. (1999) Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group Respir Med 93: 173-179.
28. Miravitlles, M., Guerrero, T., Mayordomo, C., Sánchez-Agudo, L., Nicolau, F. and Segú, J.L. (2000) Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 67: 495-501.
29. Miravitlles, M., Murio, C., Guerrero, T. and Gisbert, R. (2002) Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121: 1449-1455, DAFNE study group.
30. Miravitlles, M., Ferrer, M., Pont, A., Zalacain, R., Alvarez-Sala, J.L., Masa, J.F. et al. (2004) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. A 2 year follow-up study. Thorax 59: 387-395, IMPAC study group.
31. Miravitlles, M., Ferrer, M., Pont, A., Viejo, J.L., Masa, J.F., Gabriel, R. et al. (2005) Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers. Respir Med 99: 985-995.
32. Miravitlles, M., Anzueto, A., Legnani, D., Forstmeier, L. and Fargel, M. (2007) Patient's perception of exacerbations of COPD - the PERCEIVE study. Respir Med 101: 453-460.
33. Niederman, M.S., McCombs, J.S., Unger, A.N., Kumar, A. and Popovian, R. (1999) Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 21: 576-591.
34. Niewoehner, D.E., Rice, K., Cote, C., Paulson, D., Cooper Jr, A.D., Korducki, L. et al. (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergics bronchodilator. Ann Internal Med 143: 317-326.
35. O–Donnell, D.E., Fluge, T., Gerken, F., Hamilton, A., Webb, K., Aguilaniu, B. et al. (2004) Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23: 832-840.
36. Powrie, D.J., Wilkinson, T.M.A., Donaldson, G.C., Jones, P., Scrine, K., Viel, K. et al. (2007) Effect of tiotropium on sputum and serum inflammatory markers and exacerbations of COPD. Eur Respir J 30: 472-478.
37. Seemungal, T.A., Donaldson, G.C., Paul, E.A., Bestall, J.C., Jeffries, D.J. and Wedzicha, J.A. (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1418-1422.
38. Seemungal, T.A., Donaldson, G.C., Bhowmik, A., Jeffries, D.J. and Wedzicha, J.A. (2000) Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161: 1608-1613.
39. Sobradillo-Peña, V., Miravitlles, M., Gabriel, R., Jiménez-Ruiz, C.A., Villasante, C., Masa, J.F. et al. (2000) Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 118: 981-989.
40. Soler-Cataluña, J.J., Martinez-Garcia, M.A., Roman Sanchez, P., Salcedo, E., Navarro, M. and Ochando, R. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60: 925-931.
41. Soriano, J.B. (2007) Epidemiology of chronic obstructive pulmonary disease worldwide. Hot Topics in Resp Med 3: 13-18.
42. Spencer, S., Calverley, P.M.A., Burge, P.S. and Jones, P.W. (2001) Health status deterioration in patients with chronic obstructive pulmonay disease. Am J Respir Crit Care Med 163: 122-128, on behalf of the ISOLDE Study Group.
43. Spencer, S. and Jones, P.W. (2003) Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58: 589-593, GLOBE Study Group.
44. Stanescu, D., Sanna, A., Veriter, C., Kostianev, S., Calcagni, P.G., Fabbri, L.M. et al. (1996) Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 51: 267-271.
45. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S. et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543-1554.
46. Van Noord, J.A., Bantje Th, A., Eland, M.E., Korducki, L. and Cornelissen, P.J.G. (2000) A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 55: 289-294.
47. Vincken, W., Van Noord, J.A., Greefhorst, A.P.M., Bantje, T. h.A., Kesten, S., Korducki, L. et al. (2002) Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19: 209-216.
48. Washko, G.R., Fan, V.S., Ramsey, S.D., Mohsenifar, Z., Martinez, F., Make, B.J. et al. (2008) The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 177: 164-169.
49. Wedzicha, J.A., Calverley, P.M.A., Seemungal, T.A., Hagan, G., Ansari, Z. and Stockley, R.A. (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177: 19-26.